TORONTO--(BUSINESS WIRE)--Trimel Pharmaceuticals Corporation (TSX:TRL) today communicated its support of the U.S. Food and Drug Administration’s (FDA) decision to approve ADDYITM (flibanserin; developed by Sprout Pharmaceuticals), the first treatment option for female sexual dysfunction (FSD). Trimel is currently developing TEFINATM, a ‘use as required’, low-dose nasal testosterone gel treatment for female orgasmic disorder, a subset of FSD.
Help employers find you! Check out all the jobs and post your resume.